In spite of these limitations, this study’s findings do provide important new insights, including the downregulation of TFEB in CKD, the functional relationship between HDAC6 inhibition and TFEB activity and the reno-protective effects of HDAC6 inhibition by Tubastatin A. This evidence concerns the gene HDAC6 and chronic kidney disease.